Oppenheimer analyst Leah R. Cann maintained a Hold rating on Crispr Therapeutics AG (CRSP) today. The company’s shares closed yesterday at $38.85.
Cann wrote:
“Loss per share was $1.07, compared to our estimated loss per share of $0.59. This was the primarily the result of higher than estimated operating expenses, driven by higher R&D. R&D expenses of $39.8 million were higher than our estimated $36.4 million, due to a $15 million investment in the ViaCyte collaboration.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 6.0% and a 43.3% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $70.83.
See today’s analyst top recommended stocks >>
The company has a one-year high of $73.90 and a one-year low of $16.51. Currently, Crispr Therapeutics AG has an average volume of 958.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRISPR Therapeutics AG engages in the development and commercializtion of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.
